Hycamtin shows activity in multiple myeloma
A recent Phase II clinical study in patients with relapsed and resistant myeloma who received SmithKline Beecham's Hycamtin as a single-agent therapy demonstrated a 16% response rate and a median survival time of 28 months.
Currently available for use in treating recurrent metastatic ovarian cancer, Hycamtin is not presently indicated for use in treating multiple myeloma.
In the study, patients with refractory or relapsed multiple myeloma who had received one prior chemotherapy treatment were given Hycamtin 1.25 mg/m2 as a 30-minute infusion for five consecutive days every three weeks. Of the 43 patients evaluated, 16% exhibited at least a 50% reduction in monoclonal protein levels in the blood.